(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/245499 A1

(51) International Patent Classification:
A61K 31/44 (2006.01) *C07D 401/12* (2006.01)
A61K 31/4439 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2021/054591

(22) International Filing Date:
26 May 2021 (26.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202041023434 04 June 2020 (04.06.2020) IN

(71) Applicant: **PILLAI UNIVERSAL LLC** [US/US]; 963 Topsy Lane, 306-351, Carson City, Nevada 92590 (US).

(72) Inventors; and

(71) Applicants *(for US only)*: **PILLAI, Dr. Baskaran**; 208 Harrow Road, Pittsburgh, Pennsylvania 15238 (US). **M.G., Dinesh**; E6 SRI Kumara Krupaapartments, Suriyagandhi Street, Vivekananda Nagar, Ambattur, Chennai 600053 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

WO 2021/245499 A1

(54) **Title:** NOVEL SMALL MOLECULES FOR TARGETED DEGRADATION OF UNTARGETABLE KRAS IN CANCER THERAPY



Formula 1



Figure 6

(57) **Abstract:** The present invention discloses novel anti-cancer activity exhibiting compounds for treating subjects with chronic disorder, comprising of structure in accordance with Formula 1 or any derivative thereof, or a stereoisomer or tautomer thereof, pharmaceutically acceptable salt thereof, or combination thereof, in which X is H or alkyl group; Y is carbonyl group bonded to substituted/unsubstituted homo/hetero cyclic ring with at least one double bond or carboxyl group bonded to alkyl group; Z is carbonyl/carboxyl group bonded to substituted/unsubstituted homo/hetero cyclic ring with at least one double bond or alkene or o-alkyl substituted carbamate or carbonyl group bonded to branched alkyl group and W is H or amide group or carbonyl group bonded to branched alkyl group.

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*